Clinical Trials Browser

Completed × INDUSTRY × XL647 × Clear all

NCT00086528 2022-05-13

Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors

Phase 1 Completed

Neoplasms

NCT00336765 2022-05-13

Study of XL647 Administered Orally Daily to Patients With Solid Tumors

Phase 1 Completed

Neoplasms

NCT00364780 2022-05-13

Study of XL647 in Subjects With Non-Small-Cell Lung Cancer

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT00522145 2022-05-13

Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT02616393 2022-03-16

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Phase 2 Completed

36 enrolled 22 charts

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT02844439 2021-09-22

Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

Phase 2 Completed

40 enrolled 25 charts

Brain Neoplasms, Glioblastoma